Association for Molecular Pathology

Coalition Statement (PDF)

 

 

 

 

 

 

 

home /

Professional Societies Delineate Concerns, Offer Recommendations Regarding Interim Pricing for Molecular Tests

FOR IMMEDIATE RELEASE
May 10, 2013

Inquiries:      
Mary Steele Williams (AMP)
301-634-7921
mwilliams@amp.org                                 

Jodi Greenblatt (CAP)
202-354-7102
jgreenb@cap.org
Kathy Ridgely Beal (ACMG)
301-238-4582
kbeal@acmg.net
Sara Patterson (ASCP)
312-541-4946
ascp@ascp.org
                   
       

Bethesda, MD - Today a coalition representing over 120,000 medical and laboratory professionals and institutions that perform the vast majority of clinical molecular pathology testing in the United States released a joint statement regarding new Medicare prices for those tests.

The groups include American Association for Clinical Chemistry (AACC), American Clinical Laboratory Association (ACLA), American College of Medical Genetics and Genomics (ACMG), American Society for Clinical Pathology (ASCP), American Society for Histocompatibility and Immunogenetics (ASHI), Association for Molecular Pathology (AMP), California Clinical Laboratory Association (CCLA), College of American Pathologists (CAP) and Society for Inherited Metabolic Disorders (SIMD).

The coalition's concerns include cuts in reimbursement for molecular pathology tests, denials of claims without publication of sufficient information on the basis for those decisions, and incorrect determinations that certain tests are investigational. 

Their recommendations include removing coverage and payment restrictions, providing greater transparency about the evidence for coverage decisions and basis for payment decisions, extending the period for reconsideration of denials, and convening stakeholder meetings with CMS.

The coalition statement is available at: http://www.amp.org/about/Press_Releases/ConsensusStatement_ProfSoc(5102013).pdf

###